The external environment that we have envisaged is one where more sustainable healthcare systems are needed around the world due to factors such as global population growth and aging, the risk of new infectious diseases, technological advances and changes in social structures, and healthcare finances. Given the limited resources available, we expect the medical community to converge even faster on value-based healthcare (VBHC), where only those solutions that deliver true value are adopted.

Based on this environmental outlook, Chugai has determined a policy for investing management resources such as human resources, technology and intellectual property, collaborations with Roche and external partners, pharmaceutical technology and facilities, environment and energy, and financial and management related that are the source of value creation. Guided by our material issues for creating shared value, we will promote initiatives for value creation (value creation strategy) taking a medium- to long-term view.
Click here for more information on Chugai’s Material Issues.

Focus on innovation is key to promoting our value creation strategy. To continuously create innovative new drugs that satisfy unmet medical needs, we must explore new therapeutic targets, achieve further innovation in drug discovery technologies, and acquire a deeper understanding of biology. It is therefore important to make maximum use of our unique business model, which is based on our unique science and technology capabilities and our strategic alliance with Roche.

In designing our value creation strategy, we started by defining our vision of becoming a top innovator in the healthcare industry in 2030. Chugai needs to be a company that generates expectations from patients all over the world, attracts healthcare-related talent and players, and is a global role model that resolves social issues. TOP I 2030 is our roadmap for realizing this goal by enhancing our growth strategy and foundation for growth. To enhance the value we provide, we have formed a business structure that enables high productivity and reinvestment based on the two pillars of global first-class drug discovery and a futuristic business model. With this, we aim to double R&D output and launch in-house global products every year.

We will also enhance our foundation for growth by implementing initiatives targeting key themes including human resources and organizations, digital and quality, and environmental preservation. The areas of compliance, governance and risk management, construction of a healthy and safe business foundation, and engagement with society are not items for transformation under TOP I 2030. Rather, we will continuously maintain and evolve these throughout the Company and in each business division.

Through the promotion of this value creation strategy, Chugai will create innovative drugs that deliver true value and continuously supply them to patients worldwide. Moreover, we aim to realize a healthcare system and society where each patient can receive optimal treatment, while also achieving financial growth for the Company. We will increase our capital efficiency by building a robust earning structure and reducing risk so that we can continue to deliver R&D results over the medium to long term. In addition, we will enhance the quality of our management foundation in order to contribute to the realization of a circular economy in response to climate change and resource and energy issues.